NRAS Q61R mutation
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-NRAS-Q61R |
|---|---|
| Type | Biomarker |
| Aliases | NRAS Q61RМутація NRAS Q61R |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-MELANOMA-2025 |
Biomarker Facts
| Biomarker type | gene_mutation |
|---|---|
| Mutation details | {"exon": "3", "functional_impact": "activating (Q61 codon mutations impair GTP hydrolysis)", "gene": "NRAS", "hgvs_protein": "p.Q61R", "variant_type": "missense"} |
| Measurement | MethodTumor-tissue NGS panel; ctDNA NGS for monitoring |
| Actionability lookup | {"gene": "NRAS", "variant": "Q61R"} |
| Related biomarkers | BIO-RAS-MUTATION BIO-BRAF-V600E |
Notes
~15-20% of cutaneous melanoma; mutually exclusive with BRAF V600. Worse prognosis than BRAF-mutant disease in metastatic setting. No FDA-approved selective NRAS inhibitor. Binimetinib (NEMO trial, Dummer 2017): modest PFS benefit vs dacarbazine; not OS positive. ICI (pembrolizumab, nivolumab, nivo+ipi) remains backbone of 1L metastatic regardless of NRAS status. Q61K and Q61L are alternative Q61 substitutions — also activating, similar therapeutic implications.
Used By
Actionability
BMA-NRAS-Q61R-AML- NRAS mutations in AML (~10-15%) — adverse prognostic in some contexts; not directly targe...BMA-NRAS-Q61R-MDS-HR- NRAS in higher-risk MDS — adverse marker; HMA + venetoclax considered, alloSCT preferred.BMA-NRAS-Q61R-MDS-LR- NRAS in MDS — typically signals progression risk to AML. No targeted therapy in MDS-LR; H...BMA-NRAS-Q61R-MELANOMA- NRAS Q61R is the most common NRAS hotspot in melanoma (~20% of cutaneous melanomas). Bini...